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rash grade 1 to lower limbs after 10 days.
Immunogenicity was not assessed. None
of the patients developed influenza.
In conclusion, we did not observe
any relevant toxicity in patients with
NSCLC treated with concomitant influ-
enza vaccination and erlotinib. Although
influenza vaccines are not devoid of
risk, these data could assure clinicians
and patients that they are safe for this
subset of patients.
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Adjuvant Chemotherapy
in New Stage II pN0
Non-small Cell Lung
Cancer: A New Issue for
a Case-By-Case Decision
Making Process
To the Editor:
The seventh edition of the tumor,
node, metastasis (TNM) classification1
has raised some new issues in the adjuvant
chemotherapy decision-making process.
Previously, pN0 tumors 5 cm
were classified as stage Ib. In the new
classification, they become stage IIa
(5 but 7 cm) or stage IIb (7 cm)
because of a poorer prognosis than
smaller pN0 tumors.
According to this observation and
consistent with the Cancer-Care-Ontario
Program and the American Society of
Clinical Oncology guide-lines (based on
the sixth TNM edition),2 patients with
new stage II pN0 disease should be
informed on their prognosis, and adju-
vant chemotherapy could be proposed as
an individual option.
This issue should be carefully dis-
cussed for a case-by-case decision, ac-
cording to the available information. In
the absence of evidence-based data, we
underline the lack of definitive informa-
tion on the effect of adjuvant chemother-
apy in patients with pN0 nonsmall cell
lung cancer (NSCLC), irrespective of tu-
mor size.
As a matter of fact, this is true not
only for patients with sixth TNM stage Ib
tumors but also for patients with sixth
TNM pT3 pN0 disease. Although the lat-
ter population was gathered together with
patients with T1–T2 pN1 disease in stage
II and, so, considered for adjuvant chemo-
therapy according to ASCO guidelines, a
critical appraisal to this topic from an
extensive review of the literature showed
the absence of evidence-based data on the
efficacy of adjuvant chemotherapy for
sixth TNM pT3 pN0 tumors.3
Nevertheless, data from the CALGB
9633 phase III randomized trial should
also be shared with the patient. This trial
did not observe a significant survival ad-
vantage in patients with sixth TNM stage
Ib NSCLC, but it was underpowered to
answer this question in the population of
new stage II pN0 tumors, i.e., 5 cm.
Interestingly, in the subgroup of patients
with 4 cm disease (196 patients: 99
patients in the treatment arm and 97 pa-
tients in the control arm), there were a
significant advantage in overall survival
(hazard ratio: 0.69, 90% confidence in-
terval: 0.48–0.99) and disease-free
survival (hazard ratio: 0.69, 90% con-
fidence interval: 0.49–0.97).4
The lack of data in pT3 pN0 tumors
and the shift from stage I to stage II of
patients with 5 cm pN0 NSCLC raise
the need for information on the effects of
adjuvant chemotherapy in this subset of
patients. Major efforts to run a prospective
phase III trial to answer this question and
to select the subset of patients with higher
probability to benefit from this treatment
(if any) are warranted.
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A Systematic Review
but Systematically
Confounded?
To the Editor:
The study by Nair et al1 on the
prognostic value of positron emission to-
mography (PET) intensity in stage I non-
small cell lung cancer (NSCLC) is a su-
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